Kura Oncology (KURA) Competitors $11.25 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$11.10 -0.15 (-1.29%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KURA vs. ERAS, TWST, RCUS, TNGX, and DNLIShould you buy Kura Oncology stock or one of its competitors? MarketBeat compares Kura Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kura Oncology include Erasca (ERAS), Twist Bioscience (TWST), Arcus Biosciences (RCUS), Tango Therapeutics (TNGX), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. KURA vs. ERASKURA vs. TWSTKURA vs. RCUSKURA vs. TNGXKURA vs. DNLIHow does Kura Oncology compare to Erasca?Kura Oncology (NASDAQ:KURA) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends. Is KURA or ERAS more profitable? Erasca has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Erasca's return on equity of -35.31% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Kura Oncology-411.19% -141.95% -43.28% Erasca N/A -35.31%-29.49% Does the media prefer KURA or ERAS? In the previous week, Erasca had 5 more articles in the media than Kura Oncology. MarketBeat recorded 7 mentions for Erasca and 2 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.30 beat Erasca's score of 0.00 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, KURA or ERAS? Erasca has lower revenue, but higher earnings than Kura Oncology. Erasca is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura Oncology$67.48M14.80-$278.67M-$3.35N/AErascaN/AN/A-$124.55M-$0.93N/A Do insiders and institutionals believe in KURA or ERAS? 67.8% of Erasca shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 14.2% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, KURA or ERAS? Kura Oncology has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Erasca has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Do analysts rate KURA or ERAS? Kura Oncology currently has a consensus target price of $26.38, indicating a potential upside of 134.44%. Erasca has a consensus target price of $18.75, indicating a potential upside of 66.81%. Given Kura Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe Kura Oncology is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69Erasca 2 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryErasca beats Kura Oncology on 9 of the 15 factors compared between the two stocks.How does Kura Oncology compare to Twist Bioscience?Kura Oncology (NASDAQ:KURA) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation. Which has more volatility & risk, KURA or TWST? Kura Oncology has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.22, meaning that its share price is 122% more volatile than the broader market. Which has stronger earnings & valuation, KURA or TWST? Twist Bioscience has higher revenue and earnings than Kura Oncology. Twist Bioscience is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura Oncology$67.48M14.80-$278.67M-$3.35N/ATwist Bioscience$376.57M10.02-$77.67M-$1.33N/A Do analysts recommend KURA or TWST? Kura Oncology currently has a consensus price target of $26.38, indicating a potential upside of 134.44%. Twist Bioscience has a consensus price target of $58.00, indicating a potential downside of 4.24%. Given Kura Oncology's higher probable upside, research analysts clearly believe Kura Oncology is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69Twist Bioscience 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is KURA or TWST more profitable? Twist Bioscience has a net margin of -19.85% compared to Kura Oncology's net margin of -411.19%. Twist Bioscience's return on equity of -26.73% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Kura Oncology-411.19% -141.95% -43.28% Twist Bioscience -19.85%-26.73%-19.15% Does the media refer more to KURA or TWST? In the previous week, Twist Bioscience had 3 more articles in the media than Kura Oncology. MarketBeat recorded 5 mentions for Twist Bioscience and 2 mentions for Kura Oncology. Twist Bioscience's average media sentiment score of 0.89 beat Kura Oncology's score of 0.30 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Twist Bioscience 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTwist Bioscience beats Kura Oncology on 10 of the 14 factors compared between the two stocks.How does Kura Oncology compare to Arcus Biosciences?Arcus Biosciences (NYSE:RCUS) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation. Do insiders and institutionals believe in RCUS or KURA? 92.9% of Arcus Biosciences shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, RCUS or KURA? Arcus Biosciences has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Does the media favor RCUS or KURA? In the previous week, Kura Oncology had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 2 mentions for Kura Oncology and 1 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.87 beat Kura Oncology's score of 0.30 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Kura Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is RCUS or KURA more profitable? Arcus Biosciences has a net margin of -156.36% compared to Kura Oncology's net margin of -411.19%. Arcus Biosciences' return on equity of -68.97% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-156.36% -68.97% -35.27% Kura Oncology -411.19%-141.95%-43.28% Which has stronger earnings & valuation, RCUS or KURA? Kura Oncology has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$247M11.95-$353M-$3.18N/AKura Oncology$67.48M14.80-$278.67M-$3.35N/A Do analysts recommend RCUS or KURA? Arcus Biosciences currently has a consensus price target of $33.89, indicating a potential upside of 44.36%. Kura Oncology has a consensus price target of $26.38, indicating a potential upside of 134.44%. Given Kura Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Kura Oncology is more favorable than Arcus Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55Kura Oncology 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69 SummaryArcus Biosciences beats Kura Oncology on 9 of the 16 factors compared between the two stocks.How does Kura Oncology compare to Tango Therapeutics?Kura Oncology (NASDAQ:KURA) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership. Is KURA or TNGX more profitable? Tango Therapeutics has a net margin of -151.15% compared to Kura Oncology's net margin of -411.19%. Tango Therapeutics' return on equity of -41.54% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Kura Oncology-411.19% -141.95% -43.28% Tango Therapeutics -151.15%-41.54%-33.44% Do analysts rate KURA or TNGX? Kura Oncology presently has a consensus target price of $26.38, suggesting a potential upside of 134.44%. Tango Therapeutics has a consensus target price of $32.27, suggesting a potential upside of 59.45%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Kura Oncology is more favorable than Tango Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69Tango Therapeutics 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.64 Do insiders and institutionals have more ownership in KURA or TNGX? 79.0% of Tango Therapeutics shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, KURA or TNGX? Tango Therapeutics has lower revenue, but higher earnings than Kura Oncology. Tango Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura Oncology$67.48M14.80-$278.67M-$3.35N/ATango Therapeutics$62.38M46.93-$101.59M-$0.83N/A Which has more risk and volatility, KURA or TNGX? Kura Oncology has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Does the media favor KURA or TNGX? In the previous week, Kura Oncology and Kura Oncology both had 2 articles in the media. Kura Oncology's average media sentiment score of 0.30 beat Tango Therapeutics' score of -0.40 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTango Therapeutics beats Kura Oncology on 8 of the 14 factors compared between the two stocks.How does Kura Oncology compare to Denali Therapeutics?Denali Therapeutics (NASDAQ:DNLI) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk. Do insiders & institutionals believe in DNLI or KURA? 92.9% of Denali Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor DNLI or KURA? In the previous week, Denali Therapeutics and Denali Therapeutics both had 2 articles in the media. Kura Oncology's average media sentiment score of 0.30 beat Denali Therapeutics' score of -0.33 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kura Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, DNLI or KURA? Denali Therapeutics has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Do analysts rate DNLI or KURA? Denali Therapeutics currently has a consensus target price of $34.25, indicating a potential upside of 83.74%. Kura Oncology has a consensus target price of $26.38, indicating a potential upside of 134.44%. Given Kura Oncology's higher possible upside, analysts clearly believe Kura Oncology is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.87Kura Oncology 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69 Is DNLI or KURA more profitable? Denali Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Denali Therapeutics' return on equity of -52.20% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -52.20% -43.86% Kura Oncology -411.19%-141.95%-43.28% Which has stronger earnings and valuation, DNLI or KURA? Kura Oncology has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M8.95-$512.54M-$2.88N/AKura Oncology$67.48M14.80-$278.67M-$3.35N/A SummaryDenali Therapeutics beats Kura Oncology on 10 of the 16 factors compared between the two stocks. Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KURA vs. The Competition ExportMetricKura OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$998.71M$3.37B$6.45B$12.34BDividend YieldN/A2.26%2.76%5.28%P/E Ratio-3.3610.3417.9322.89Price / Sales14.80323.98553.9286.28Price / CashN/A125.1743.4956.67Price / Book9.227.0910.377.14Net Income-$278.67M$24.45M$3.57B$335.98M7 Day Performance22.28%5.45%6.01%3.56%1 Month Performance21.49%2.43%3.52%2.54%1 Year Performance99.47%62.98%34.13%35.05% Kura Oncology Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KURAKura Oncology2.44 of 5 stars$11.25flat$26.38+134.4%+99.5%$998.71M$67.48MN/A130ERASErasca3.2219 of 5 stars$10.27+0.4%$18.75+82.6%+821.3%$3.18BN/AN/A120Gap UpTWSTTwist Bioscience1.7264 of 5 stars$49.79+1.3%$56.57+13.6%+114.3%$3.06B$376.57MN/A990Analyst ForecastGap UpRCUSArcus Biosciences3.6528 of 5 stars$23.43-1.5%$33.89+44.7%+159.5%$2.99B$247MN/A500TNGXTango Therapeutics2.4414 of 5 stars$20.63+0.3%$32.27+56.4%+1,000.0%$2.97B$56.99MN/A90Gap Up Related Companies and Tools Related Companies ERAS Alternatives TWST Alternatives RCUS Alternatives TNGX Alternatives DNLI Alternatives ALMS Alternatives GMTX Alternatives BEAM Alternatives DYN Alternatives MOR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KURA) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
